1700019M22Rik Activators engage distinct cellular signaling mechanisms to potentiate theactivity of the protein. Compounds such as Forskolin and Dibutyryl-cAMP work by elevating intracellular cAMP levels, thereby activating protein kinase A (PKA). If 1700019M22Rik is a substrate for PKA, or if its regulatory mechanism includes cAMP signaling, these activators would enhance its activity through PKA-dependent phosphorylation. Similarly, IBMX and Rolipram prolong the cAMP signal by inhibiting phosphodiesterases, thereby sustaining PKA signaling that could lead to the enhanced function of 1700019M22Rik. PMA, an activator of protein kinase C (PKC), could phosphorylate 1700019M22Rik directly or influence its activity by altering PKC-dependent signaling pathways. Ionomycin, by increasing intracellular calcium levels, may activate calcium/calmodulin-dependent protein kinases, potentially influencing 1700019M22Rik if calcium signaling is implicated in its modulation.
Furthermore, Epigallocatechin gallate, by inhibiting certain protein kinases, may favor the activation of 1700019M22Rik by mitigating inhibitory phosphorylation events. Inhibitors of key signaling molecules such as LY294002, U0126, and SB203580, which target PI3K, MEK, and p38 MAPK, respectively, can indirectly enhance the activity of 1700019M22Rik by shifting the equilibrium of their respective pathways. For instance, in the context of PI3K/Akt signaling, LY294002 might increase 1700019M22Rik activity by disrupting inhibitory feedback loops. The mTOR inhibitor Rapamycin could activate autophagy-related pathways, potentially enhancing the activity of 1700019M22Rik if it plays a role in autophagic processes. Lastly, AICAR activates AMPK, which serves as a cellular energy sensor; the activation of AMPK could lead to the enhanced function of 1700019M22Rik if it is regulated by cellular energy status. Collectively, these chemical activators employ a multifaceted approach to bolster the functional activity of 1700019M22Rik through modulation of signaling pathways and cellular processes that are hypothesized to regulate its activity.
SEE ALSO...
| Product Name | CAS # | Catalog # | QUANTITY | Price | Citations | RATING |
|---|---|---|---|---|---|---|
PMA | 16561-29-8 | sc-3576 sc-3576A sc-3576B sc-3576C sc-3576D | 1 mg 5 mg 10 mg 25 mg 100 mg | $41.00 $132.00 $214.00 $500.00 $948.00 | 119 | |
PMA activates protein kinase C (PKC). If 1700019M22Rik is part of a pathway downstream of PKC, its activity could be enhanced by PKC-mediated phosphorylation processes. | ||||||
Ionomycin | 56092-82-1 | sc-3592 sc-3592A | 1 mg 5 mg | $78.00 $270.00 | 80 | |
Ionomycin increases intracellular calcium levels, potentially activating calcium-dependent kinases such as calmodulin kinase. These kinases could then activate 1700019M22Rik if it is part of calcium-dependent signaling pathways. | ||||||
(−)-Epigallocatechin Gallate | 989-51-5 | sc-200802 sc-200802A sc-200802B sc-200802C sc-200802D sc-200802E | 10 mg 50 mg 100 mg 500 mg 1 g 10 g | $43.00 $73.00 $126.00 $243.00 $530.00 $1259.00 | 11 | |
EGCG acts as a kinase inhibitor, potentially altering the balance of kinase activity within cells. This could indirectly enhance the activity of 1700019M22Rik if it is regulated by kinases that are sensitive to EGCG. | ||||||
LY 294002 | 154447-36-6 | sc-201426 sc-201426A | 5 mg 25 mg | $123.00 $400.00 | 148 | |
LY294002 is a PI3K inhibitor. If 1700019M22Rik is activated as part of the PI3K/Akt pathway, the inhibition of PI3K could result in compensatory mechanisms that enhance the activity of 1700019M22Rik. | ||||||
SB 203580 | 152121-47-6 | sc-3533 sc-3533A | 1 mg 5 mg | $90.00 $349.00 | 284 | |
SB203580 is a p38 MAPK inhibitor, which may lead to the activation of alternative pathways that could involve 1700019M22Rik if it is part of stress response signaling. | ||||||
A23187 | 52665-69-7 | sc-3591 sc-3591B sc-3591A sc-3591C | 1 mg 5 mg 10 mg 25 mg | $55.00 $131.00 $203.00 $317.00 | 23 | |
A23187 acts as a calcium ionophore, raising intracellular calcium levels and potentially activating 1700019M22Rik through calcium-dependent pathways. | ||||||
PD 98059 | 167869-21-8 | sc-3532 sc-3532A | 1 mg 5 mg | $40.00 $92.00 | 212 | |
PD98059 is an MEK inhibitor that could lead to the activation of alternate signaling routes, potentially involving 1700019M22Rik if it functions within those compensatory pathways. | ||||||